Juan Carlos López Bernaldo de Quirós

Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials

Pedro Cahn, Juan Sierra Madero, José Ramón Arribas et al. · The Lancet · 2018 · 381 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +17

Maintenance of Large Numbers of Virus-Specific CD8+ T Cells in HIV-Infected Progressors and Long-Term Nonprogressors

Juan Gea‐Banacloche, Stephen A. Migueles, Lisa Martino et al. · The Journal of Immunology · 2000 · 264 citations · Full text

Life Sciences, Immunology, Infectious Diseases +17

A Randomized Trial of the Discontinuation of Primary and Secondary Prophylaxis against<i>Pneumocystis carinii</i>Pneumonia after Highly Active Antiretroviral Therapy in Patients with HIV Infection

Juan Carlos López Bernaldo de Quirós, José M. Miró, José M. Peña et al. · New England Journal of Medicine · 2001 · 205 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +17

Discontinuation of Maintenance Therapy for Cryptococcal Meningitis in Patients with AIDS Treated with Highly Active Antiretroviral Therapy: An International Observational Study

Cristina Mussini, Patrizio Pezzotti, José M. Miró et al. · Clinical Infectious Diseases · 2004 · 124 citations · Full text

Life Sciences, Immunology, Infectious Diseases +15

Safety and immunogenicity of a modified pox vector-based HIV/AIDS vaccine candidate expressing Env, Gag, Pol and Nef proteins of HIV-1 subtype B (MVA-B) in healthy HIV-1-uninfected volunteers: A phase I clinical trial (RISVAC02)

Felipe García, Juan Carlos López Bernaldo de Quirós, Carmen Gómez et al. · Vaccine · 2011 · 80 citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +17